Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
2019년 8월 15일 업데이트: Merck Sharp & Dohme LLC
A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in addition to diet and exercise therapy.
The primary hypothesis of the study is that omarigliptin 25 mg once weekly provides greater reduction in hemoglobin A1C (HbA1c) compared with placebo as assessed by change from baseline to Week 16 [Phase A (double-blind period)].
연구 개요
상세 설명
After a screening period of up to 2 weeks followed by a pretreatment period of 2 or 10 weeks, each participant will be receiving assigned double-blind treatment (omarigliptin 25 mg or placebo once weekly) for approximately 16 weeks (Phase A) followed by 36 weeks of open-label treatment (omarigliptin 25 mg once weekly, Phase B).
After the end of treatment each participant will be followed for 21 days.
연구 유형
중재적
등록 (실제)
184
단계
- 4단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
20년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Have T2DM
Meet all of following criteria at Week -2 of pre-randomization
- On diet and exercise therapy for 6 weeks or longer, AND
- Have been on a stable dosage and administration of insulin (8 to 40 units/day) for 10 weeks or longer, AND.
- Have not been on any additional anti-hyperglycemic agent (AHAs, except for insulin monotherapy) for 8 weeks or longer, AND
- HbA1c ≥7.5% and ≤10.0%
- Fasting Plasma Glucose (FPG) ≥126 mg/dL and ≤230 mg/dL
- Have a body mass index (BMI) >18 kg/m^2 and <40 kg/m^2
- A male or female not of reproductive potential or a female of reproductive potential and agrees to remain abstinent from heterosexual activity, or agrees to use acceptable contraception to prevent pregnancy.
Exclusion Criteria:
- Has type 1 diabetes mellitus or has a history of diabetic ketoacidosis.
Has a history of being administered any of the following AHAs including fixed dose combination (FDC) containing the following ingredients:
- Thiazolidinediones within 12 weeks
- Glucagon-like peptide 1 (GLP-1) receptor agonists within 12 weeks
- Omarigliptin at any time
- Has history of severe hypoglycemia with coma or loss of consciousness, or for whom hypoglycemia was observed greater or equal to two times per week within 8 weeks
- Is currently participating in or has participated in another study with an investigational compound or device within the prior 12 weeks
- Has undergone a surgical procedure within 8 weeks or has planned major surgery during the study.
- Receives a lipid-lowering medication or thyroid replacement therapy at unstable dosage and administration
- Has poorly controlled hypertension
- Has a medical history of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.
- Has human immunodeficiency virus (HIV).
- Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder within the past 3 months
- Has severe peripheral vascular disease.
- Has a history of malignancy ≤ 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer:
- Has a clinically important hematological disorder.
- (For women of childbearing potential) has a positive urine pregnancy test.
- Is pregnant or breast feeding
- Is expected to conceive during the study
- Is expected to undergo hormonal therapy in preparation to donate eggs during the study
- Routinely consumes >14 alcoholic drinks per week or engages in binge drinking
- Has donated or plans to donate blood products of >300 mL within 8 weeks or during the study
- Has received or plans to receive blood products within 12 weeks or during the study
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Omarigliptin 25 mg
Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
|
Omarigliptin, 25 mg orally once weekly
다른 이름들:
Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
|
|
실험적: Placebo→Omarigliptin 25 mg
Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
|
Omarigliptin, 25 mg orally once weekly
다른 이름들:
Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
Placebo to omarigliptin orally once weekly
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Constrained Longitudinal Data Analysis of Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
기간: Baseline (Day 1) and Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participant whole blood samples were collected at baseline and Week 16 to determine the Constrained Longitudinal Data Analysis least squares mean HbA1c change from baseline (i.e., HbA1c at Week 16 minus HbA1c at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Negative data values indicated a reduction in HbA1c levels.
|
Baseline (Day 1) and Week 16
|
|
Percentage of Participants Who Experienced One or More Adverse Events (AE) Excluding Data After Glycemic Rescue (Phase A)
기간: Up to Week 16
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
|
Up to Week 16
|
|
Percentage of Participants Who Experienced One or More AE (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only])
기간: Up to Week 52
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
The results for the Placebo→Omarigliptin group summarized data from the open label period only (36 weeks), which corresponds to the study interval in which those participants were exposed to omarigliptin.
|
Up to Week 52
|
|
Percentage of Participants Who Discontinued Study Drug Due to an AE Excluding Data After Glycemic Rescue (Phase A)
기간: Up to Week 16
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
|
Up to Week 16
|
|
Percentage of Participants Who Discontinued Study Drug Due to an AE Including Data After Glycemic Rescue (Omarigliptin [Phase A+B]; Placebo→Omarigliptin [Phase B Only])
기간: Up to Week 52
|
An adverse event is defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.
Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
The results for the Placebo→Omarigliptin group summarized data from the open label period only (36 weeks), which corresponds to the study interval in which those participants were exposed to omarigliptin.
|
Up to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Constrained Longitudinal Data Analysis of Change From Baseline in Fasting Plasma Glucose (FPG) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
기간: Baseline (Day 1) and Week 16
|
Blood glucose was measured on a fasting basis.
FPG is expressed as mg/dL.
Blood was drawn at predose on Day 1 and after 16 weeks of treatment to determine Constrained Longitudinal Data Analysis change in plasma glucose levels (i.e., FPG at Week 16 minus FPG at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Negative data values indicated a reduction in FPG levels.
|
Baseline (Day 1) and Week 16
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<7.0%) at Week 16 Constrained Longitudinal Data Analysis Using Multiple Imputation Excluding Data After Glycemic Rescue (Phase A)
기간: Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Each of the 10 imputed data sets was summarized to obtain the percentage of responders within each group and were combined using standard multiple imputation techniques to yield an overall estimate of response rate and associated variance for each group.
A constrained longitudinal data analysis was used to analyze the data and Wilson score method by treatment groups used for the analysis of percentages of individuals at the HbA1c goals of <7.0% at Week 16 and the 95% confidence intervals (CIs).
Miettinen & Nurminen (M&N) method after imputations were used to calculate the treatment differences of the percentages of individuals and the 95% CIs.
|
Week 16
|
|
Percentage of Participants Achieving HbA1c Goals (<6.5%) at Week 16 Constrained Longitudinal Data Analysis Using Multiple Imputation Excluding Data After Glycemic Rescue (Phase A)
기간: Week 16
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Each of the 10 imputed data sets was summarized to obtain the percentage of responders within each group and were combined using standard multiple imputation techniques to yield an overall estimate of response rate and associated variance for each group.
A constrained longitudinal data analysis was used to analyze the data and Wilson score method by treatment groups used for the analysis of percentages of individuals at the HbA1c goals of <6.5% at Week 16 and the 95% confidence intervals (CIs).
Miettinen & Nurminen (M&N) method after imputations were used to calculate the treatment differences of the percentages of individuals and the 95% CIs.
|
Week 16
|
|
Constrained Longitudinal Data Analysis of Change From Baseline in 1,5-anhydroglucitol (1,5-AG) at Week 16 Excluding Data After Glycemic Rescue (Phase A)
기간: Baseline (Day 1) and Week 16
|
1,5-anhydroglucitol (1,5-AG) is a marker of short-term glycemic control especially postprandial hyperglycemia.
1,5-AG accurately predicts rapid changes in glycemia and is tightly associated with glucose fluctuations and postprandial glucose.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Data after glycemic rescue were excluded from this analysis.
Data (1,5-AG at Week 16 minus 1,5-AG at baseline) was analyzed by Constrained Longitudinal Data Analysis.
Positive data values indicate an increase in 1,5-AG levels and correlate with an improvement in glycemia.
|
Baseline (Day 1) and Week 16
|
|
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52 (Phase A+B)
기간: Baseline (Day 1) and Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participant whole blood samples were collected at baseline and Week 52 to determine the mean HbA1c change from baseline (i.e., HbA1c at Week 52 minus HbA1c at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Negative data values indicated a reduction in HbA1c levels.
|
Baseline (Day 1) and Week 52
|
|
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Phase A+B)
기간: Baseline (Day 1) and Week 52
|
Blood glucose was measured on a fasting basis.
FPG is expressed as mg/dL.
Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at baseline).
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
Negative data values indicated a reduction in FPG levels.
|
Baseline (Day 1) and Week 52
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<7.0%) at Week 52 (Phase A+B)
기간: Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
For the HbA1c goals of <7.0% at Week 52, the percentage of participants and the 95% confidence intervals were calculated using Wilson score method by treatment groups of the double-blind period.
|
Week 52
|
|
Percentage of Participants Achieving Hemoglobin A1c Goals (<6.5%) at Week 52 (Phase A+B)
기간: Week 52
|
HbA1c is a measure of the percentage of glycated hemoglobin in the blood.
Participants that met rescue criteria had their insulin dose adjusted as determined clinically appropriate by the investigator to manage glycemic control.
For the HbA1c goals of <6.5% at Week 52, the percentage of participants and the 95% confidence intervals were calculated using Wilson score method by treatment groups of the double-blind period.
|
Week 52
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2016년 10월 17일
기본 완료 (실제)
2018년 8월 21일
연구 완료 (실제)
2018년 8월 21일
연구 등록 날짜
최초 제출
2016년 9월 15일
QC 기준을 충족하는 최초 제출
2016년 9월 15일
처음 게시됨 (추정)
2016년 9월 20일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2019년 9월 19일
QC 기준을 충족하는 마지막 업데이트 제출
2019년 8월 15일
마지막으로 확인됨
2019년 8월 1일
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 3102-039
- MK-3102-039 (기타 식별자: Merck Protocol Number)
- 163455 (레지스트리 식별자: JAPIC-CTI)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
예
IPD 계획 설명
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .